A Phase IB Study of REGN910 and Aflibercept plus Paclitaxel in Women with Recurrent Ovarian Cancer

Full Title
A Phase 1b Study of Combined Angiogenesis Inhibition by Administering REGN910 and Aflibercept in Patients with Advanced Solid Malignancies

One way to treat cancer is to inhibit the development of the blood vessels that cancers need to grow and spread (a process called angiogenesis). Aflibercept and REGN910 are both “anti-angiogenesis” drugs. Aflibercept works by targeting a protein involved in angiogenesis called VEGF. REGN910 targets another angiogenesis protein, called Ang2.

Aflibercept is already approved for treating advanced colorectal cancer and, as an injection, for an eye disease; its use in ovarian cancer is considered investigational. REGN910 is also investigational. In this study, researchers want to find the highest doses of aflibercept and REGN910 that can be given safely in combination with paclitaxel in women with ovarian cancer that has come back within six months of treatment with carboplatin or cisplatin.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have locally advanced or metastatic ovarian cancer that has returned within six months of the last dose of carboplatin or cisplatin therapy.
  • Patients may have had up to 3 prior regimens of platinum-based therapy but no more than 7 total systemic therapy regimens.
  • At least 3 weeks must have passed since completion of prior therapy and entry into the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is open to patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Jason Konner at 646-888-4219.

Ovarian Cancer
Related Diseases